Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. (Q54367200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Massimo Sabbatini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Luigi Russo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Francesco Cappellaio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Giancarlo Troncone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Preziosa Buonocore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Eleonora Riccio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Vincenzo Bisesti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Stefano Federico

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

19 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Physiology - Renal Physiology

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

F1243-50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption in man.

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Design-based stereology: introduction to basic concepts and practical approaches for estimation of cell number

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Polycystic kidney disease: neoplasia in disguise

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Tolvaptan inhibits ERK-dependent cell proliferation, Cl−secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00694.2013

10.1152/AJPRENAL.00694.2013

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24647711%20AND%20SRC:MED&resulttype=core&format=json